{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"complete cytogenetic remission"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"partial cytogenetic remission"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"no cytogenetic remission"}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"description":"Described as the number of patients with a major cytogenetic response (refers to disappearance of a cytogenetic abnormality) or a minor cytogenetic response (50% or more reduction of abnormal metaphases).","groups":[{"description":"INDUCTION PHASE: Patients receive decitabine subcutaneously (SQ) twice weekly for 4 weeks or thrice weekly until achieving bone marrow blasts \\< 5%. MAINTENANCE PHASE: Patients then receive decitabine SQ twice weekly for up to 52 weeks in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Arm I: Decitabine 0.2mg/kg"}],"paramType":"NUMBER","populationDescription":"Patients that had cytogenetic abnormalities at baseline and were evaluable with follow-up metaphase karyotyping.","reportingStatus":"POSTED","timeFrame":"at 12 months","title":"Cytogenetic Response as Per IWG Criteria","type":"SECONDARY","unitOfMeasure":"participants"}